Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cholanic acid compounds for preventing or treating fxr-mediated diseases

A compound, cholanoic acid technology, applied in the field of medicine, can solve problems such as increasing energy consumption

Active Publication Date: 2019-01-08
SHENZHEN TARGETRX INC
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

While the activation of this membrane receptor in macrophages reduces the production of pro-inflammatory cytokines, the stimulation of TGR5 by bile acids in adipocytes and muscle cells increases energy consumption

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cholanic acid compounds for preventing or treating fxr-mediated diseases
  • Cholanic acid compounds for preventing or treating fxr-mediated diseases
  • Cholanic acid compounds for preventing or treating fxr-mediated diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Example 1 Preparation of 3α, 7α-di-hydroxyl-7-d-6α-ethyl-5β-cholanic acid (compound 7)

[0062]

[0063] Concrete synthetic steps are as follows:

[0064]

[0065]

[0066] Step 1: Synthesis of methyl α-hydroxy-7-keto-5β-cholanate (compound 2).

[0067] Two drops of concentrated sulfuric acid were added dropwise to 3α-hydroxy-7-keto-5β-cholanic acid (5.00 g, 12.80 mmol) in methanol, and reflux reaction (65° C.) for 3 hrs. Concentrate under reduced pressure to remove methanol, concentrate liquid column chromatography to obtain 4.60 g colorless solid (compound 2), yield: 88.3%.

[0068] LC-MS(APCI):m / z=405.3[M+1] + .

[0069] Step 2: Synthesis of methyl α-7α-di-trimethylsilyloxy-5β-cholanate (compound 3).

[0070] At -78°C, trimethylchlorosilane (7.15 mL, 57.0 mmol) was added dropwise to a solution of lithium diisopropylamide (LDA 2M, 34.2 mL, 68.4 mmol) in anhydrous tetrahydrofuran (70 mL), and stirred for 30 minutes. Then a mixture of 3α-hydroxy-7-keto-5β...

Embodiment 2

[0083] Example 2 Preparation of 3α, 7α-di-hydroxyl-6α-(ethyl-1-d)-5β-cholanic acid (compound 10)

[0084]

[0085] Concrete synthetic steps are as follows:

[0086]

[0087] Step 1: Synthesis of methyl 3α-hydroxy-6α-(ethyl-1-d)-6-d-7-keto-5β-cholanate (compound 8).

[0088] Pd / C (10%, 55% in D 2 2, 60 mg) was added to 3α-hydroxy-6-ethylidene-7-keto-5β-cholanoic acid methyl ester (600 mg, 1.39 mmol) in anhydrous tetrahydrofuran and deuterated methanol (20 mL, 1:1 v / v ) in a mixed solvent. The air was replaced by deuterium gas, and the reaction was stirred overnight under deuterium gas. Filtrate with celite, concentrate under reduced pressure, and purify by column chromatography to obtain 420 mg of light yellow oil, yield: 70.0%.

[0089] LC-MS(APCI):m / z=435.3[M+1] + .

[0090] Step 2: Synthesis of 3α-hydroxy-6α-(ethyl-1-d)-7-keto-5β-cholanic acid (Compound 9).

[0091] Sodium hydroxide (120mg, 2.90mmol) was added to 3α-hydroxy-6α-(ethyl-1-d)-6-d-7-keto-5β-cholano...

Embodiment 3

[0096] Example 3 Preparation of 3α, 7α-di-hydroxyl-6α-ethyl-6-d-5β-cholanic acid (compound 12)

[0097]

[0098] Concrete synthetic steps are as follows:

[0099]

[0100] Step 1: Synthesis of 3α-hydroxy-6α-ethyl-6-d-7-keto-5β-cholanic acid (Compound 11).

[0101] Sodium deuterated oxide (120 mg, 2.90 mmol) was added to methyl 3α-hydroxy-6α-ethyl-7-keto-5β-cholanate (420 mg, 0.97 mmol) in deuterated methanol and heavy water (20 mL, 1: 1v / v) in a mixed solvent, the reaction was stirred overnight, methanol was removed under reduced pressure, diluted with water (20mL), acidified with 2N HCl, extracted with ethyl acetate (50mL x3), the organic layer was washed with saturated brine, anhydrous sulfuric acid Sodium dry. The organic layer was concentrated under reduced pressure, and the concentrate was purified by column chromatography to obtain 280 mg of white solid, yield: 68.8%.

[0102] LC-MS(APCI):m / z=418.1[M-1] - .

[0103] Step 3: Synthesis of 3α,7α-di-hydroxy-6α-(...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a cholanic acid compound for preventing or treating FXR-mediated diseases. Specifically, disclosed are a cholanic acid compound represented by formula (I) and a pharmaceutical composition containing the compound, or a crystalline form, a pharmaceutically-acceptable salt, a prodrug, a tautomer, a stereoisomer, an enantiomer, and a hydrate or a solvate thereof. The compound in the present invention can be used as a farnesol X receptor agonist and can therefore be applied to the preparation of drugs for treating FXR-related diseases (for example, fatty liver).

Description

technical field [0001] The invention belongs to the field of medicine. Specifically, the present invention relates to a cholanic acid compound for preventing or treating FXR-mediated diseases, its pharmaceutical composition and use. Background technique [0002] Farnesoid X receptor (FXR) is a member of the orphan nuclear receptor family. It was first discovered by Forman et al. in 1995. It is named because its transcriptional activity can be enhanced by farnesoid at supraphysiological concentrations. Northern and in situ analysis revealed that FXR is abundantly expressed in the lung, intestine, kidney, and adrenal gland. FXR forms a heterodimer with 9-cis retinoic acid receptor (RXR) and binds to DNA. The FXR / RXR heterodimer binds preferentially to a component consisting of binuclear receptor half-sites sharing the AG(G / T)TCA, which form inverted repeats and separate single nucleosides (IR-1 motif). However, these compounds fail to activate mouse and human FXR, making th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07J9/00C07B59/00A61K31/575A61P35/00A61P1/16A61P1/00A61P13/12A61P9/00A61P3/00A61P3/04A61P3/10
CPCA61K31/575C07B59/00C07J9/00
Inventor 王义汉任兴业
Owner SHENZHEN TARGETRX INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com